MX365985B - Antagonistas de il-6 para aumentar la albumina y/o disminuir la crp. - Google Patents
Antagonistas de il-6 para aumentar la albumina y/o disminuir la crp.Info
- Publication number
- MX365985B MX365985B MX2014004474A MX2014004474A MX365985B MX 365985 B MX365985 B MX 365985B MX 2014004474 A MX2014004474 A MX 2014004474A MX 2014004474 A MX2014004474 A MX 2014004474A MX 365985 B MX365985 B MX 365985B
- Authority
- MX
- Mexico
- Prior art keywords
- antagonists
- antibodies
- patient
- preferred embodiments
- survivability
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/248—IL-6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Virology (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biochemistry (AREA)
- Hospice & Palliative Care (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
Abstract
La presente invención se refiere a el uso de un antagonista de interleucina 6 (IL-6), para preparar un medicamento para preparar un medicamento para mejorar la capacidad de supervivencia o la calidad de vida de un paciente que lo necesita, por el cual; (i) el nivel de proteína C reactiva en suero ("CRP") del paciente se reduce, y/o (ii) el nivel de albúmina sérica del paciente aumenta y, además, en donde el antagonista de IL-6 comprende un anti-IL-6 o fragmento de anticuerpo cuyo anticuerpo anti-IL-6 comprende un polipéptido VL que comprende los polipéptidos CDR de la SEQ ID NO; 103; SEQ ID NO: 104; y la SEQ ID NO: 105 y un polipéptido VH que comprende los polipéptidos en donde la administración de dicho anticuerpo o fragmento de anticuerpo mejora la capacidad de supervivencia o la calidad de vida del paciente que lo necesita reduciendo el nivel de proteína c reactiva en suero ("CRP") del paciente y/o aumentando el nivel de albúmina sérica del paciente.
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11781108P | 2008-11-25 | 2008-11-25 | |
US11786108P | 2008-11-25 | 2008-11-25 | |
US11783908P | 2008-11-25 | 2008-11-25 | |
US12/366,567 US8062864B2 (en) | 2007-05-21 | 2009-02-05 | Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies |
US39161509A | 2009-02-24 | 2009-02-24 | |
US12/391,717 US8178101B2 (en) | 2007-05-21 | 2009-02-24 | Use of anti-IL-6 antibodies having specific binding properties to treat cachexia |
US12/399,156 US20090238825A1 (en) | 2007-05-21 | 2009-03-06 | Novel rabbit antibody humanization methods and humanized rabbit antibodies |
US12/502,581 US8323649B2 (en) | 2008-11-25 | 2009-07-14 | Antibodies to IL-6 and use thereof |
PCT/US2009/006257 WO2010065072A1 (en) | 2008-11-25 | 2009-11-24 | Antagonists of il-6 to raise albumin and/or lower crp |
Publications (1)
Publication Number | Publication Date |
---|---|
MX365985B true MX365985B (es) | 2019-06-21 |
Family
ID=42233511
Family Applications (7)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2014004474A MX365985B (es) | 2008-11-25 | 2009-11-24 | Antagonistas de il-6 para aumentar la albumina y/o disminuir la crp. |
MX2011005396A MX2011005396A (es) | 2008-11-25 | 2009-11-24 | Antagonistas de il-6 para aumentar la albumina y/o disminuir la crp. |
MX2011005408A MX2011005408A (es) | 2008-11-25 | 2009-11-24 | Antagonistas de il-6 para prevenir o tratar la trombosis. |
MX2011005411A MX2011005411A (es) | 2008-11-25 | 2009-11-24 | Anticuerpos de il-6 y uso de los mismos. |
MX2014008792A MX364874B (es) | 2008-11-25 | 2009-11-24 | Anticuerpos de il-6 y uso de los mismos. |
MX2019005415A MX2019005415A (es) | 2008-11-25 | 2011-05-20 | Anticuerpos de il-6 y uso de los mismos. |
MX2019007500A MX2019007500A (es) | 2008-11-25 | 2011-05-20 | Antagonistas de il-6 para aumentar la albumina y/o disminuir la crp. |
Family Applications After (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2011005396A MX2011005396A (es) | 2008-11-25 | 2009-11-24 | Antagonistas de il-6 para aumentar la albumina y/o disminuir la crp. |
MX2011005408A MX2011005408A (es) | 2008-11-25 | 2009-11-24 | Antagonistas de il-6 para prevenir o tratar la trombosis. |
MX2011005411A MX2011005411A (es) | 2008-11-25 | 2009-11-24 | Anticuerpos de il-6 y uso de los mismos. |
MX2014008792A MX364874B (es) | 2008-11-25 | 2009-11-24 | Anticuerpos de il-6 y uso de los mismos. |
MX2019005415A MX2019005415A (es) | 2008-11-25 | 2011-05-20 | Anticuerpos de il-6 y uso de los mismos. |
MX2019007500A MX2019007500A (es) | 2008-11-25 | 2011-05-20 | Antagonistas de il-6 para aumentar la albumina y/o disminuir la crp. |
Country Status (19)
Country | Link |
---|---|
EP (5) | EP2361095B1 (es) |
JP (9) | JP5620918B2 (es) |
KR (4) | KR20110112307A (es) |
CN (5) | CN103861106B (es) |
AR (1) | AR074227A1 (es) |
AU (5) | AU2009323007B2 (es) |
BR (1) | BRPI0921569A2 (es) |
CA (1) | CA2744400C (es) |
DK (1) | DK3338799T3 (es) |
EA (1) | EA201100641A1 (es) |
HK (1) | HK1256622A1 (es) |
IL (2) | IL212728B (es) |
MX (7) | MX365985B (es) |
NO (1) | NO2367570T3 (es) |
NZ (2) | NZ602166A (es) |
SG (1) | SG171804A1 (es) |
TW (6) | TWI533883B (es) |
WO (4) | WO2010065079A2 (es) |
ZA (1) | ZA201103803B (es) |
Families Citing this family (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11046784B2 (en) | 2006-03-31 | 2021-06-29 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
US8062864B2 (en) | 2007-05-21 | 2011-11-22 | Alderbio Holdings Llc | Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies |
US8252286B2 (en) | 2007-05-21 | 2012-08-28 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat thrombosis |
US8178101B2 (en) | 2007-05-21 | 2012-05-15 | Alderbio Holdings Inc. | Use of anti-IL-6 antibodies having specific binding properties to treat cachexia |
NZ597767A (en) | 2007-05-21 | 2013-06-28 | Bristol Myers Squibb Co | Antibodies to IL-6 and use thereof |
US8404235B2 (en) | 2007-05-21 | 2013-03-26 | Alderbio Holdings Llc | Antagonists of IL-6 to raise albumin and/or lower CRP |
US9701747B2 (en) | 2007-05-21 | 2017-07-11 | Alderbio Holdings Llc | Method of improving patient survivability and quality of life by anti-IL-6 antibody administration |
US7906117B2 (en) | 2007-05-21 | 2011-03-15 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever |
CA2700394C (en) | 2007-09-26 | 2017-10-24 | Chugai Seiyaku Kabushiki Kaisha | Modified antibody constant region |
MX369784B (es) | 2007-09-26 | 2019-11-21 | Chugai Pharmaceutical Co Ltd | Metodo de modificacion del punto isoelectrico de anticuerpos mediante la sustitucion de aminoacidos en region de determinacion de complementariedad (cdr). |
CN107551270A (zh) | 2008-04-11 | 2018-01-09 | 中外制药株式会社 | 与多个分子的抗原反复结合的抗原结合分子 |
TWI440469B (zh) | 2008-09-26 | 2014-06-11 | Chugai Pharmaceutical Co Ltd | Improved antibody molecules |
KR20110112307A (ko) * | 2008-11-25 | 2011-10-12 | 앨더 바이오파마슈티컬즈, 인코포레이티드 | 알부민을 상승시키고 및/또는 crp를 낮추는 il6의 길항제 |
US9212223B2 (en) | 2008-11-25 | 2015-12-15 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat thrombosis |
US8992920B2 (en) | 2008-11-25 | 2015-03-31 | Alderbio Holdings Llc | Anti-IL-6 antibodies for the treatment of arthritis |
US8337847B2 (en) | 2008-11-25 | 2012-12-25 | Alderbio Holdings Llc | Methods of treating anemia using anti-IL-6 antibodies |
US8323649B2 (en) | 2008-11-25 | 2012-12-04 | Alderbio Holdings Llc | Antibodies to IL-6 and use thereof |
US8420089B2 (en) | 2008-11-25 | 2013-04-16 | Alderbio Holdings Llc | Antagonists of IL-6 to raise albumin and/or lower CRP |
US9452227B2 (en) | 2008-11-25 | 2016-09-27 | Alderbio Holdings Llc | Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments |
US7947653B1 (en) | 2009-10-09 | 2011-05-24 | Cold Spring Harbor Laboratory | Methods for treating epidermal growth factor receptor tyrosine kinase inhibitor-resistant cancers |
US8323883B1 (en) | 2009-10-09 | 2012-12-04 | Cold Spring Harbor Laboratory | Methods of assessing therapeutic benefits of patients having cancers resistant to epidermal growth factor receptor kinase inhibitors |
CN102740888B (zh) * | 2009-11-24 | 2016-10-12 | 奥尔德生物制药公司 | Il-6抗体及其用途 |
US9775921B2 (en) | 2009-11-24 | 2017-10-03 | Alderbio Holdings Llc | Subcutaneously administrable composition containing anti-IL-6 antibody |
JP2012041271A (ja) * | 2010-08-12 | 2012-03-01 | Univ Of Tokyo | 血栓形成を抑制する作用を有する組成物 |
TWI603738B (zh) | 2010-11-08 | 2017-11-01 | 建南德克公司 | 皮下投予抗-il-6受體抗體 |
ES2847891T3 (es) | 2010-11-23 | 2021-08-04 | Vitaeris Inc | Anticuerpos anti-IL-6 para el tratamiento de la mucositis oral |
RU2658504C9 (ru) | 2010-11-30 | 2018-08-21 | Чугаи Сейяку Кабусики Кайся | Антигенсвязывающая молекула, способная многократно связываться с множеством антигенных молекул |
CN104066428A (zh) * | 2011-10-12 | 2014-09-24 | 思佰益药业股份有限公司 | 抗癌剂的副作用的预防剂和/或治疗剂 |
JO3370B1 (ar) * | 2011-11-10 | 2019-03-13 | Regeneron Pharma | طريقة لتثبيط نمو الورم عن طريق تثبيط مستقبل انترلوكين 6 |
KR102124758B1 (ko) * | 2012-05-03 | 2020-06-19 | 베링거 인겔하임 인터내셔날 게엠베하 | 항-il-23p19 항체 |
DK4019041T3 (da) | 2012-07-13 | 2023-04-03 | Univ Pennsylvania | Toksicitetshåndtering for cars antitumoraktivitet |
EP2875360B1 (en) * | 2012-07-20 | 2018-08-08 | Agency For Science, Technology And Research | In vitro assay for predicting renal proximal tubular cell toxicity |
CN104797132B (zh) * | 2012-09-13 | 2017-06-30 | 中外制药株式会社 | 基因敲入非人动物 |
EP2722341B1 (en) | 2012-10-22 | 2017-12-06 | Fountain Biopharma Inc. | Antibodies to interleukin-6 and uses thereof |
RS60026B1 (sr) | 2013-02-18 | 2020-04-30 | Vegenics Pty Ltd | Molekuli koji vezuju ligande i njihove upotrebe |
KR101332836B1 (ko) * | 2013-05-15 | 2013-11-27 | 재단법인 통합의료진흥원 | 자음강화탕을 포함하는 유방암 치료용 조성물 |
WO2014200018A1 (ja) | 2013-06-11 | 2014-12-18 | 独立行政法人 国立精神・神経医療研究センター | 再発寛解型多発性硬化症(rrms)患者の治療予後予測方法、及び新規治療適応判断方法 |
WO2015054293A1 (en) * | 2013-10-07 | 2015-04-16 | Alder Biopharmaceuticals, Inc. | Anti-il-6 antibodies for the treatment of psoriatic arthritis |
CN103739672B (zh) * | 2013-12-31 | 2015-06-10 | 威特曼生物科技(南京)有限公司 | 一种聚乙二醇修饰的抑制vegfr2酪氨酸激酶多肽及其应用 |
EP2926815A1 (en) * | 2014-04-03 | 2015-10-07 | Institut Curie | New derivatives of cephalosporin for treating cancer |
JO3663B1 (ar) * | 2014-08-19 | 2020-08-27 | Merck Sharp & Dohme | الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين |
CN104147120A (zh) * | 2014-09-04 | 2014-11-19 | 成都市飞龙水处理技术研究所 | 一种治疗多发性神经纤维瘤的内服中药液及其制备方法 |
CN107074976B (zh) * | 2014-11-04 | 2020-10-09 | 北京韩美药品有限公司 | 同时阻断b7/cd28和il6/il6r/gp130信号通路的重组融合蛋白 |
TWI805046B (zh) | 2015-02-27 | 2023-06-11 | 日商中外製藥股份有限公司 | Il-6受體抗體用於製備醫藥組成物的用途 |
US10697883B2 (en) | 2015-05-19 | 2020-06-30 | National Center Of Neurology And Psychiatry | Method for determining application of therapy to multiple sclerosis (MS) patient |
US11174317B2 (en) | 2015-06-04 | 2021-11-16 | National Center Of Neurology And Psychiatry | Therapeutic agent for mental illness comprising IL-6 inhibitor as active ingredient |
SG10201913062SA (en) * | 2015-07-31 | 2020-03-30 | Medimmune Ltd | Methods for treating hepcidin-mediated disorders |
CN105586426B (zh) * | 2016-03-01 | 2019-02-26 | 浙江大学 | 与慢性乙型肝炎病毒感染相关的IL-6基因rs2069852位点标志物及其应用 |
KR102055390B1 (ko) * | 2017-01-06 | 2019-12-12 | 경북대학교 산학협력단 | 혈전-표적성 펩타이드, 페리틴 단편 및 혈전 용해성 펩타이드를 포함하는 융합 펩타이드 및 이의 용도 |
AU2018214554C1 (en) | 2017-02-01 | 2022-12-15 | Novo Nordisk A/S | Treatment of diuretic resistance |
US11851486B2 (en) | 2017-05-02 | 2023-12-26 | National Center Of Neurology And Psychiatry | Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils |
US11452707B2 (en) * | 2017-08-31 | 2022-09-27 | Hanyi Bio-Technology (Beijing) Co., Ltd. | Use of cannabidiol in preparation of drugs for resisting against influenza |
JP7235249B2 (ja) | 2017-10-20 | 2023-03-08 | 学校法人兵庫医科大学 | 抗il-6受容体抗体を含有する術後の癒着を抑制するための医薬組成物 |
WO2019103138A1 (ja) * | 2017-11-24 | 2019-05-31 | 国立研究開発法人理化学研究所 | IL‐1β及び/又はIL‐6の発現抑制剤とその利用 |
JP2021509915A (ja) * | 2018-01-04 | 2021-04-08 | ヴィタエリス、インコーポレイテッド | 固形臓器移植レシピエントの脱感作のため、及び/または抗体媒介性拒絶反応(abmr)の予防、安定化、もしくは軽減のための抗il−6抗体、例えば、クラザキズマブの使用 |
MX2020007033A (es) * | 2018-01-05 | 2021-02-26 | Immunext Inc | Anticuerpos anti-mct1 y usos de estos. |
JP7395479B2 (ja) | 2018-01-05 | 2023-12-11 | ノヴォ ノルディスク アー/エス | 免疫抑制なしにil-6媒介性炎症を処置する方法 |
US20210071183A1 (en) * | 2018-02-26 | 2021-03-11 | The Trustees Of Columbia University In The City Of New York | Zinc associated treatment for and diagnosis of cachexia |
JP7336717B2 (ja) | 2018-09-26 | 2023-09-01 | パナソニックIpマネジメント株式会社 | 開閉ユニット、開閉機能付きコンセント、および、それらの生産方法 |
US11633399B2 (en) | 2018-12-25 | 2023-04-25 | Sol-Gel Technologies Ltd. | Treatment of skin disorders with compositions comprising an EGFR inhibitor |
CN110297093B (zh) * | 2019-03-18 | 2022-04-22 | 山西瑞豪生物科技有限公司 | 一种检测人免疫球蛋白g4的方法和试剂盒 |
CA3160091A1 (en) | 2019-11-05 | 2021-05-14 | Abbvie Inc. | Dosing regimens for use in treating myelofibrosis and mpn-related disorders with navitoclax |
CN111053909A (zh) * | 2020-02-27 | 2020-04-24 | 南通大学 | 2019-nCoV3CL水解酶抑制剂与IL-6单抗在制备治疗新冠肺炎药物中的应用 |
EP4121455A1 (en) * | 2020-03-18 | 2023-01-25 | Vitaeris Inc. | Use of anti-il-6 antibody, e.g., clazakizumab for treatment/prevention of ards associated with coronavirus (covid-19) infection |
CN112098549B (zh) * | 2020-09-03 | 2022-11-15 | 长沙创新药物工业技术研究院有限公司 | 一种测定盐酸阿比多尔溶液中杂质含量的方法 |
CN112175080B (zh) * | 2020-10-22 | 2021-05-25 | 优睿赛思(武汉)生物科技有限公司 | 抗人白介素-6高亲和力兔单克隆抗体及应用 |
KR20230113306A (ko) | 2020-10-30 | 2023-07-28 | 고쿠리츠켄큐카이하츠호진 고쿠리츠쥰칸키뵤 겐큐센터 | 주산기 심근증 치료제 |
WO2022188013A1 (zh) * | 2021-03-08 | 2022-09-15 | 苏州大学 | 化学发光介导的纳米颗粒、自组装聚集体及其制备方法和应用 |
WO2023182801A1 (ko) * | 2022-03-24 | 2023-09-28 | (주) 테라베스트 | 자연살해세포를 포함하는 퇴행성 뇌질환 예방 또는 치료용 약학 조성물 |
Family Cites Families (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5202422A (en) | 1989-10-27 | 1993-04-13 | The Scripps Research Institute | Compositions containing plant-produced glycopolypeptide multimers, multimeric proteins and method of their use |
US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
US5210075A (en) | 1990-02-16 | 1993-05-11 | Tanabe Seiyaku Co., Ltd. | Interleukin 6 antagonist peptides |
WO1992002551A1 (en) | 1990-08-02 | 1992-02-20 | B.R. Centre Limited | Methods for the production of proteins with a desired function |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
ATE255131T1 (de) | 1991-06-14 | 2003-12-15 | Genentech Inc | Humanisierter heregulin antikörper |
WO1994021293A1 (en) | 1993-03-19 | 1994-09-29 | Duke University | Method of treatment of tumors with an antibody binding to tenascin |
TW458985B (en) | 1993-05-31 | 2001-10-11 | Chugai Pharmaceutical Co Ltd | Reconstructed human antibody against human interleukin-6 |
EP1624068A1 (en) | 1993-06-01 | 2006-02-08 | Life Technologies Inc. | Genetic immunization with cationic lipids |
AU3272695A (en) | 1994-08-12 | 1996-03-07 | Immunomedics Inc. | Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells |
ATE423790T1 (de) | 1995-09-28 | 2009-03-15 | Yeda Res & Dev | Synthetische peptide mit il-6 aktivitäthemmung |
US6841533B1 (en) | 1995-12-07 | 2005-01-11 | Peptor Limited | Conformationally constrained backbone cyclized interleukin-6 antagonists |
US6653104B2 (en) | 1996-10-17 | 2003-11-25 | Immunomedics, Inc. | Immunotoxins, comprising an internalizing antibody, directed against malignant and normal cells |
EP2210945B1 (en) * | 1998-01-14 | 2013-06-26 | Novartis Vaccines and Diagnostics S.r.l. | Neisseria meningitidis antigens |
EP0972780A1 (en) | 1998-05-18 | 2000-01-19 | Applied Research Systems ARS Holding N.V. | Il-6 antagonist peptides |
US7345217B2 (en) * | 1998-09-22 | 2008-03-18 | Mendel Biotechnology, Inc. | Polynucleotides and polypeptides in plants |
IL139380A0 (en) * | 2000-10-31 | 2001-11-25 | Prochon Biotech Ltd | Active variants of fibroblast growth factor |
US20040198661A1 (en) * | 2000-12-08 | 2004-10-07 | Bowdish Katherine S. | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
US7169573B2 (en) * | 2001-02-20 | 2007-01-30 | Oklahoma Medical Research Foundation | Method for monitoring coagulability and hypercoagulable states |
JP2003066047A (ja) * | 2001-06-14 | 2003-03-05 | Matsushita Electric Ind Co Ltd | 免疫反応測定方法及びそれに用いる免疫反応測定用試薬 |
US20030219839A1 (en) * | 2001-09-20 | 2003-11-27 | Katherine Bowdish | Anti-PDGF antibodies and methods for producing engineered antibodies |
EP2308888B1 (en) * | 2001-11-14 | 2017-03-01 | Janssen Biotech, Inc. | Anti-IL-6 antibodies, compositions, methods and uses |
KR100468316B1 (ko) | 2002-01-29 | 2005-01-27 | 주식회사 웰진 | Dna의 세포 또는 조직 내 전달 효율을 높이는 펩타이드 |
CA2492524A1 (en) * | 2002-08-15 | 2004-02-26 | Epitomics, Inc. | Humanized rabbit antibodies |
CN1678744B (zh) | 2002-08-30 | 2010-05-26 | 财团法人化学及血清疗法研究所 | 人的抗人白细胞介素-6抗体以及所述抗体的片段 |
US20050090453A1 (en) | 2003-01-15 | 2005-04-28 | Solbec Pharmaceuticals Co., Ltd. | Methods of modulating IL-6 |
US20070010529A1 (en) | 2003-05-19 | 2007-01-11 | Kanji Takahashi | Nitrogenous heterocyclic compounds and medical use thereof |
US20070134242A1 (en) * | 2003-10-17 | 2007-06-14 | Chugai Seiyaku Kabushiki Kaisha | Mesothelioma therapeutic agent |
DK2330201T3 (en) | 2003-10-22 | 2017-07-24 | Keck Graduate Inst | PROCEDURES FOR SYNTHESIS OF HEATER-MULTIMATE POLYPEPTIDES WHEN USING A HAPLOID COUPLE STRATEGY |
CA2572119A1 (en) * | 2004-06-29 | 2006-01-12 | Warner-Lambert Company Llc | Combination therapies utilizing benzamide inhibitors of the p2x7 receptor |
GB0419424D0 (en) | 2004-09-02 | 2004-10-06 | Viragen Scotland Ltd | Transgene optimisation |
WO2006047639A2 (en) * | 2004-10-27 | 2006-05-04 | Medimmune, Inc. | Modulation of antibody specificity by tailoring the affinity to cognate antigens |
US20080033027A1 (en) * | 2005-03-21 | 2008-02-07 | Vicus Therapeutics Spe 1, Llc | Drug combination pharmaceutical compositions and methods for using them |
US7431927B2 (en) * | 2005-03-24 | 2008-10-07 | Epitomics, Inc. | TNFα-neutralizing antibodies |
PE20061324A1 (es) * | 2005-04-29 | 2007-01-15 | Centocor Inc | Anticuerpos anti-il-6, composiciones, metodos y usos |
KR101422523B1 (ko) | 2005-12-09 | 2014-07-24 | 유씨비 파마, 에스.에이. | 사람 il6에 특이성을 지니는 항체 분자 |
US8080528B2 (en) * | 2005-12-22 | 2011-12-20 | The Releef Initiative | Compositions and methods for treatment of cachexia |
DK1966244T3 (da) * | 2005-12-30 | 2012-04-23 | Merck Patent Gmbh | Anti-il-6-antistoffer der forebygger bindingen af il-6 sammensat af il-6ralfa til gp130 |
EP2010214A4 (en) * | 2006-04-10 | 2010-06-16 | Abbott Biotech Ltd | USES AND COMPOSITIONS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS |
AU2007307324B2 (en) * | 2006-05-19 | 2013-08-15 | Alder Biopharmaceuticals, Inc. | Culture method for obtaining a clonal population of antigen-specific B cells |
WO2007139359A1 (en) * | 2006-05-31 | 2007-12-06 | Hanwha Chemical Corporation | Vcam-1 specific monoclonal antibody |
US7919095B2 (en) * | 2006-08-03 | 2011-04-05 | Vaccinex, Inc. | Anti-IL-6 monoclonal antibodies |
WO2008042611A2 (en) | 2006-09-29 | 2008-04-10 | Centocor, Inc. | Method of using il6 antagonists with mitoxantrone for prostate cancer |
TW200831528A (en) * | 2006-11-30 | 2008-08-01 | Astrazeneca Ab | Compounds |
US8178101B2 (en) | 2007-05-21 | 2012-05-15 | Alderbio Holdings Inc. | Use of anti-IL-6 antibodies having specific binding properties to treat cachexia |
TWI609965B (zh) * | 2007-05-21 | 2018-01-01 | 艾爾德生物控股有限責任公司 | 新穎兔抗體人化方法以及經人化之兔抗體 |
NZ597767A (en) * | 2007-05-21 | 2013-06-28 | Bristol Myers Squibb Co | Antibodies to IL-6 and use thereof |
US8062864B2 (en) | 2007-05-21 | 2011-11-22 | Alderbio Holdings Llc | Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies |
KR20110112307A (ko) * | 2008-11-25 | 2011-10-12 | 앨더 바이오파마슈티컬즈, 인코포레이티드 | 알부민을 상승시키고 및/또는 crp를 낮추는 il6의 길항제 |
US11783908B2 (en) | 2019-10-11 | 2023-10-10 | SK Hynix Inc. | Stacked semiconductor device and semiconductor system including the same |
-
2009
- 2009-11-24 KR KR1020117014629A patent/KR20110112307A/ko not_active Application Discontinuation
- 2009-11-24 WO PCT/US2009/006274 patent/WO2010065079A2/en active Application Filing
- 2009-11-24 CN CN201410058493.4A patent/CN103861106B/zh active Active
- 2009-11-24 MX MX2014004474A patent/MX365985B/es unknown
- 2009-11-24 KR KR1020117014632A patent/KR20110112308A/ko not_active Application Discontinuation
- 2009-11-24 AU AU2009323007A patent/AU2009323007B2/en not_active Ceased
- 2009-11-24 NO NO09830697A patent/NO2367570T3/no unknown
- 2009-11-24 NZ NZ602166A patent/NZ602166A/en not_active IP Right Cessation
- 2009-11-24 EP EP09830692.1A patent/EP2361095B1/en not_active Not-in-force
- 2009-11-24 SG SG2011037496A patent/SG171804A1/en unknown
- 2009-11-24 WO PCT/US2009/006273 patent/WO2010065078A1/en active Application Filing
- 2009-11-24 NZ NZ592516A patent/NZ592516A/xx unknown
- 2009-11-24 AU AU2009323002A patent/AU2009323002B2/en active Active
- 2009-11-24 CN CN200980155124.4A patent/CN102292449B/zh active Active
- 2009-11-24 EP EP09830696.2A patent/EP2361096B1/en active Active
- 2009-11-24 CA CA2744400A patent/CA2744400C/en active Active
- 2009-11-24 MX MX2011005396A patent/MX2011005396A/es active IP Right Grant
- 2009-11-24 AU AU2009323009A patent/AU2009323009B2/en active Active
- 2009-11-24 CN CN200980155120.6A patent/CN102292106B/zh active Active
- 2009-11-24 EP EP09830695.4A patent/EP2376126B1/en not_active Not-in-force
- 2009-11-24 DK DK17194768.2T patent/DK3338799T3/da active
- 2009-11-24 JP JP2011537432A patent/JP5620918B2/ja active Active
- 2009-11-24 MX MX2011005408A patent/MX2011005408A/es active IP Right Grant
- 2009-11-24 JP JP2011537437A patent/JP5898496B2/ja active Active
- 2009-11-24 WO PCT/US2009/006266 patent/WO2010065077A2/en active Application Filing
- 2009-11-24 BR BRPI0921569A patent/BRPI0921569A2/pt not_active IP Right Cessation
- 2009-11-24 CN CN200980155125.9A patent/CN102292107B/zh active Active
- 2009-11-24 EA EA201100641A patent/EA201100641A1/ru unknown
- 2009-11-24 MX MX2011005411A patent/MX2011005411A/es active IP Right Grant
- 2009-11-24 EP EP17194768.2A patent/EP3338799B1/en active Active
- 2009-11-24 CN CN200980155121.0A patent/CN102438653B/zh not_active Expired - Fee Related
- 2009-11-24 EP EP09830697.0A patent/EP2367570B1/en active Active
- 2009-11-24 KR KR1020117014634A patent/KR20110091780A/ko not_active Application Discontinuation
- 2009-11-24 WO PCT/US2009/006257 patent/WO2010065072A1/en active Application Filing
- 2009-11-24 JP JP2011537436A patent/JP5832292B2/ja active Active
- 2009-11-24 KR KR1020117014636A patent/KR20110091781A/ko not_active Application Discontinuation
- 2009-11-24 JP JP2011537433A patent/JP5832291B2/ja not_active Expired - Fee Related
- 2009-11-24 AU AU2009323008A patent/AU2009323008B2/en not_active Ceased
- 2009-11-24 MX MX2014008792A patent/MX364874B/es unknown
- 2009-11-25 TW TW098140116A patent/TWI533883B/zh active
- 2009-11-25 TW TW104119976A patent/TWI617318B/zh not_active IP Right Cessation
- 2009-11-25 TW TW98140118A patent/TWI469793B/zh not_active IP Right Cessation
- 2009-11-25 TW TW098140115A patent/TWI481413B/zh not_active IP Right Cessation
- 2009-11-25 AR ARP090104558A patent/AR074227A1/es unknown
- 2009-11-25 TW TW103136468A patent/TWI547502B/zh not_active IP Right Cessation
- 2009-11-25 TW TW098140117A patent/TWI498120B/zh not_active IP Right Cessation
-
2011
- 2011-05-05 IL IL212728A patent/IL212728B/en active IP Right Grant
- 2011-05-20 MX MX2019005415A patent/MX2019005415A/es unknown
- 2011-05-20 MX MX2019007500A patent/MX2019007500A/es unknown
- 2011-05-24 ZA ZA2011/03803A patent/ZA201103803B/en unknown
-
2014
- 2014-09-18 JP JP2014189695A patent/JP5815098B2/ja not_active Expired - Fee Related
-
2015
- 2015-05-22 JP JP2015104877A patent/JP6035373B2/ja active Active
- 2015-05-26 JP JP2015106107A patent/JP6050431B2/ja active Active
- 2015-05-26 JP JP2015106045A patent/JP6050430B2/ja active Active
-
2016
- 2016-10-31 JP JP2016213750A patent/JP6190028B2/ja not_active Expired - Fee Related
- 2016-11-11 AU AU2016256810A patent/AU2016256810B2/en not_active Ceased
-
2018
- 2018-02-01 IL IL257290A patent/IL257290A/en unknown
- 2018-12-10 HK HK18115754.4A patent/HK1256622A1/zh unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2019007500A (es) | Antagonistas de il-6 para aumentar la albumina y/o disminuir la crp. | |
WO2011066369A3 (en) | Antagonists of il-6 to raise albumin and/or lower crp | |
EA200970262A1 (ru) | Композиции и способы, относящиеся к антителам к глюкагоновым рецепторам | |
EA200702064A1 (ru) | Новое анти-plgf антитело | |
MX2012007318A (es) | Proteina de fusion de la region constante del anticuerpo-cd47 tetravalente para usarse en terapia. | |
EA201070730A1 (ru) | Гуманизированные антитела, специфичные к фактору фон виллебранда | |
MX2009002151A (es) | Anticuerpos monoclonales humanos especificos para light humano antagonistas. | |
EA200700136A1 (ru) | Анти-cd154-антитела | |
TN2010000201A1 (en) | Anti-hepcidin antibodies and uses thereof | |
EA200870274A1 (ru) | ПЕПТИДЫ, БЛОКИРУЮЩИЕ СВЯЗЫВАНИЕ IgG C FcRn | |
ATE548657T1 (de) | Prozedur zur strukturellen charakterisierung rekombinanter polyclonaler proteine oder einer polyclonalen zelllinie | |
EA200901436A1 (ru) | Антигенсвязывающие белки, связывающие par-2 | |
DE602004014117D1 (de) | Thiazole zur verwendung als inhibitoren von protein-kinasen | |
RU2007139452A (ru) | СПОСОБЫ И КОМПОЗИЦИИ ДЛЯ МОДУЛИРОВАНИЯ ГИПЕРСТАБИЛИЗИРОВАННОГО c-met | |
WO2005120557A3 (en) | Inhibition of macrophage-stimulating protein receptor (ron) | |
EA202192090A1 (ru) | Антигенсвязывающие белки против гамма-цепи рецептора il2 | |
DE60315815D1 (de) | ANTAGONISTISCHE HUMANE ANTI-hFAS-LIGAND-ANTIKÖRPER UND FRAGMENTE DAVON | |
EA202100199A1 (ru) | Моноклональные антитела, специфически связывающиеся с trbv-9 человека | |
MX338563B (es) | Antagonistas de il-6 para prevenir o tratar la caquexia, la debilidad, la fatiga y/o la fiebre. | |
MX2022003159A (es) | Anticuerpos contra el factor de las celulas madre y metodos de uso de ellos. | |
WO2007007160A3 (en) | Anti-madcam antibodies to treat fever | |
TH138888A (th) | แอนทาโกนิสต์ของ il-6 เพื่อเพิ่มอัลบูมิน และ/หรือ ลด crp | |
EA202092477A1 (ru) | Антитела против галектина-10 | |
MX2022005595A (es) | Método para tratar o mejorar el síndrome de cushing usando proteínas de unión para el receptor peptídico inhibidor gástrico (gipr). | |
WO2008010980A3 (en) | Tat-049 and methods of assessing and treating cancer |